This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
0 genotypes. In June 2019, the European Commission (EC) granted conditional marketing authorisation for Zynteglo to treat transfusion-dependent beta-thalassemia. The latest approval is based on findings from the Phase III clinical trials, HGB-207 (Northstar-2) and HGB-212 (Northstar-3), and the long-term follow-up LTF-303 study.
The congenital fibrinogen deficiency (CFD) market is expected to grow at a compound annual growth rate (CAGR) of 1.7% through 2031, reaching over $800m across the three major markets (3MM: US, Germany, and Japan), according to GlobalData’s recent report: Congenital Fibrinogen Deficiency: Opportunity Assessment and Forecast.
The European Commission (EC) has expanded marketing authorisation for Gilead’s Epclusa (sofosbuvir/velpatasvir/sofosbuvir) to include the treatment of children with chronic hepatitis C infection (HCV).
The decision allows use of the therapy in the EU in children as young as six years of age.
Source link.
The US Food and Drug Administration (FDA) has granted marketing authorization to Cepheid for its groundbreaking Xpert HCV test and GeneXpert Xpress System, marking a significant advancement in the diagnosis and treatment of hepatitis C virus (HCV). North America dominated the market in 2018 with a 47.46 percent share.
Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It is administered through intravenous route.
bluebird bio has presented long-term data from its Zinteglo one-time gene therapy for the blood disorder beta-thalassaemia, as the company continues talks with payers in Europe to bring the ultra-pricey treatment to market. In Europe bluebird has set a price of up to $1.58 million euros for a single shot.
Food and Drug Administration announced it has made a low-risk determination for the marketing of products, including food, from two genome-edited beef cattle and their offspring after determining that the intentional genomic alteration (IGA) does not raise any safety concerns (low-risk determination).
Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction.
Hepatitis C treatment options, without a doubt, have improved significantly, including pan-genotypic medications that are used to treat all genotypes and subtypes. Typically, pan-genotypic treatments have high cure rates, few side effects, and short treatment durations (usually 8–12 weeks). and GT2 and GT3 with ribavirin.
ONWARD is investigating Adial’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. The European market is expected to be similar in size. ” About Adial Pharmaceuticals, Inc.
Moreover, the test will also allow clinicians to monitor the evolution of a patient’s tumor genotype during the course of therapy through serial and almost real-time assessments; this will help to better guide treatment decisions and care.
This database should support automatic importation from hospitals, laboratories and surveillance networks and link to genotypic data when available.”. The medicines needed to treat resistant infections are complicated to develop and have a relatively small market both in terms of duration of use, usually only a few days, and need,” it said.
The program is aiming to genotype roughly 150,000 participants over the next few years to demonstrate the impact personalised testing can have on a large scale. In the near future, more testing must be put into place and standardised throughout the industry. The post How Pharmacogenomics may finally realise its promise appeared first on.
It identifies bacteria using both genotypic and phenotypic assessments within 1.5 He goes on to say, “No medical device currently in the market is able to conduct an antibiotics combination test to either confirm or predict if a combination is effective. fAST: Automated Bacteria Identification and Multiple Antibiotics Combination Test.
Rather than be provided a therapy that has been tested across a broad range of the population, there are now many therapies on the market that are designed specifically to work for sub-populations within disease areas. Recent years have brought a revolution to the way in which patients receive treatment.
TIB Molbiol is a biotech company that has supplied the global market with reagents for research and medical diagnostics for over 30 years. To support customers performing human genotyping, TIB Molbiol provides custom made LightSNiP assays for SNP analysis. About TIB Molbiol.
It is worth mentioning that molecular diagnostics is a subset of the broader in vitro diagnostics market. According to the World Health Organization, there are over 40,000 in vitro diagnostics products available in the market. Such test can be used for gene expression profiling, genotyping and detecting chromosomal abnormalities.
3, and Delta ([link] About TIB Molbiol TIB Molbiol is a subsidiary of Roche Diagnostics that has supplied the global market with reagents for research and medical diagnostics for over 30 years. To support customers performing human genotyping, TIB Molbiol provides custom-made LightSNiP assays for SNP analysis.
The worldwide market for neurology clinical trials stood at a valuation of $5.24 To accurately identify these genetic factors, genotyping techniques such as Sanger sequencing, next-generation sequencing (NGS) and copy number variant analysis are used. billion in 2022. It’s projected to grow at a compound annual growth rate (CAGR) of 5.6
Current Approaches / Processes for Offering Genomic Tests Presently, owing to the significant reduction in the cost of genotyping and sequencing, there has been a significant rise in the number of nutrigenomics companies offering genetic testing services directly to the consumers without the involvement of clinicians.
On November 19, the European Commission granted marketing authorization for Oxlumo for the treatment of PH1 in all age groups, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).
They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing. . Johnson and Johnson are evaluating a variety of drugs for several indications that may soon join the respective market in the upcoming years. The global healthcare spending in 2020 was USD 8.3 trillion in 2021.
Anti-P-selectin antibody Adakveo became the first new treatment for VOCs in SCD patients in decades when it was approved for marketing in the EU, a few months after the FDA gave it the nod in the US, on the strength of the SUSTAIN trial results. That study showed that Adakveo lowered the median annual rate of VOCs to 1.63 compared to 2.98
As per the WHO, more than 100 types of HPV are found worldwide, out of them at least 13 known HPV genotypes can cause cancer of the cervix. A number of antiretroviral drugs are available in the market today, that can be combined in different ways. Presently many pipeline therapies are under development for the Genital Herpes.
The market for cannabis-infused products is growing like weed. The legalization of the plant for medical and recreational applications has led to profound growth of this market across the globe. Cannabis testing is also done to identify the plant genotype used to develop the product, providing transparency to the consumers.
This is an increase from the EMA’s approval of two novel ATMPs with orphan designation in 2021 (although the marketing authorization for one of these ATMPs was withdrawn in the European Union in November 2021) and three novel ATMPs with orphan designation in 2020. How Can Study Protocols Be More Effective? “A
While there are commonly used HPV tests in the market, not all are approved for primary screening and only provide limited information about the different genotypes of HPV present. Molecular testing for HPV types that are known to cause cervical cancer is certainly welcome as Pap tests are invasive and can be uncomfortable.
The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. The incidence of Grade 3-4 neutropenia in genotyped patients was 69% in patients homozygous for the UGT1A1*28, 48% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele.
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content